<DOC>
	<DOC>NCT02370537</DOC>
	<brief_summary>This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to investigate the pharmacokinetics (PK) of EPANOVA® (omega-3 carboxylic acids) and omega-3-acid ethyl esters (OMACOR®, Abbott Healthcare Products Ltd) following a single oral dose in patients with different degrees of PEI.</brief_summary>
	<brief_title>A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Male or female aged ≥18 years and ≤70 years, with suitable veins for cannulation or repeated venipuncture. Clinically diagnosed Type 2 diabetics (American Diabetes Association guidelines;), on oral antibiotic drug use ≥3 months and HbA1c value ≥6.5% and ≤9.0% at Visit 1. Have a body mass index ≥18 kg/m2 and ≤40 kg/m2 and weigh at least 50 kg. Intolerance to Omega3 fatty acids, ethyl esters or fish. On insulin therapy or treated with injectable Glucagonlike peptide1 (GLP1). Treated with bile acid sequestrants. Serum levels of TGs &gt;10 mmol/L at any time during the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>omega-3 carboxylic acid</keyword>
</DOC>